Table 1. Clinical characteristics of patients on hemodialysis in the city of Crato, CE.

	With residual function	Without residual function	p
N	27	24
Shift
MWF (%)	81.5	88	0.515†
Age (years)	46. 81 ± 16.38	52.50 ± 17.16	0.232#
Male (%)	48.5	70.8	0.100†
Residual diuresis (mL)	930 ± 423.3
Urea clearance (mL/min)	2.61 ± 2.13	-
Creatinine clearance (mL/min)	5.42 ± 3.13
Mean urea and creatinine clearance (mL/min)	3.68 ± 2.12
Vascular access arteriovenous fistula (%)	87.5	95.8	0.739†
Base Disease (%)			0.327†
Hypertension	37	20.8
Diabetes	3.7	4.2
Glomerulonephritis	11.1	16.7
ADPKD	14.8	8.3
Obstructive Uropathy	18.5	12.5
Unknown	14.8	37.5
Hemodialysis vintage (years)	2.10 ± 1.91	7.20 ± 3.13	< 0.001#
KT/V	1.31 ± 0.36	1.22 ± 0.28	0.36#
Adequate KTV (%)	74.1	70.8	0.79†
Antihypertensive drugs that cause Hyperkalemia			0.395†
(ACEI / ARB / Spironolactone / Beta-Blocker) (%)
None	33.3	50
One	59.3	41.7
Two	7.4	4.2
Three	0.0	4.2
Four	0.0	0.0
Diuretic (%)	18.5	8.3	0.291†
Other Antihypertensives (%)			0.729†
None	66.7	62.5
One	22.2	25
Two	7.4	12.5
Three	3.7	0.0
Erythropoietin (%)			0.528†
Did not use	7.4	12.5
≤ 4000 U / week	44.4	25
Between 4000 and 8000 U / Week	11.1	16.7
> 8000 U / week	37	45.8
Sevelamer (%)			0.873†
Did not use	66.7	66.7
1 tablet/day	0.0	0.0
2 tablets /day	14.8	12.5
3 tablets/day	11.1	16.7
≥ 4 tablets/day	7.4	4.2
Calcium carbonate (%)			0.018†
Do not use	74.1	62.5
1 tablet /day	14.8	0.0
2 tablets /day	7.4	4.2
3 tablets /day	3.7	4.2
≥ 4 tablets/day	0.0	29.2
Calcitriol			0.476†
Did not use	77.8	66.7
1 tablets/day	14.8	16.7
2 tablets/day	3.7	12.5
3 tablets /day	0.0	4.2

^†X2 (linear by linear)

^#t-test for independent samples